Our lead program candidate, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein designed to provide potential long-acting attack prevention for HAE.

STAR-0215 is in clinical development for the treatment of hereditary angioedema. After receiving positive preliminary results from our Phase 1a trial in healthy subjects, we initiated our ALPHA-STAR proof of concept Phase 1b/2 trial in people living with HAE in early 2023.

Learn how STAR-0215 aims to prevent attacks in HAE by exploring the mechanism of action here:


  • STAR-0215 is currently in clinical development for the treatment of HAE.
  • Positive results from our Phase 1a clinical trial of STAR-0215 in healthy subjects demonstrate early proof of concept for STAR-0215 as a potential HAE therapy with a favorable safety profile, long half-life, and durable pharmacodynamics. These results confirm the potential for STAR-0215 to prevent HAE attacks with dosing 2 or 4 times per year.
  • We are evaluating STAR-0215 in people living with HAE. We initiated in Q1 2023. We expect initial proof-of-concept results from the ALPHA-STAR Phase 1b/2 trial in HAE patients in Q1 2024.


Preclinical results to date show STAR-0215’s differentiated profile, with high potency and a long plasma half-life, predicting that STAR-0215 could be an effective preventative therapy with the potential for dosing once every 3 and 6 months.


We’ve heard from the HAE community the desire to normalize their lives, living without limitations from their symptoms and treatments. Our goal is to reduce the disease and treatment burden for people living with HAE, whose current options for preventative therapies require frequent administration (daily or up to every 4 weeks). We believe we can do better with STAR-0215.

Based on the near-term HAE treatment landscape, our Phase 1a data support our vision that STAR-0215 can become the new standard of care for HAE attack prevention.

We are driven to help patients and families normalize their lives by developing a treatment that allows them to focus their time and energy on what matters most to them.